Research on the role of circulating tumour DNA (ctDNA) in metastatic castration-resistant prostate cancer (mCRPC) gains momentum, as a new study finds ctDNA assessment promising in the monitoring and prognosis of mCRPC and in identifying new therapeutic targets for the disease.
A recent study presented at the ASCO Genitourinary Cancers Symposium 2017 held in Orlando, Florida, US showed that antibiotic use in patients with metastatic renal cell carcinoma (mRCC) may dampen the efficacy of PD-1/PD-L1 inhibitors.
Patients with castration-resistant prostate cancer (CRPC) may be able to reduce treatment cost by taking low-dose abiraterone acetate with a low-fat breakfast as a study shows noninferiority of the regimen compared with standard dosing on an empty stomach.
Some patients with metastatic renal cell carcinoma (mRCC) who respond to PD-1/PD-L1 immunotherapy can have persistent clinical benefit after treatment discontinuation due to immune-related adverse events.
Asia's trusted medical magazine for healthcare professionals.
Get your MIMS Doctor - Malaysia digital copy today!
Dr Michael Lim, a senior consultant at the Paediatric Pulmonary and Sleep Division, National University Hospital, Singapore, speaks to Roshini Claire Anthony on the rare disease that is cystic fibrosis.
Empagliflozin treatment in patients with type 2 diabetes mellitus exerts beneficial effects on cardiovascular (CV) risk factors, including blood pressure and uric acid, according to a systematic review and meta-analysis.
A 10 or 20 mg/kg daily dose of cannabidiol could almost halve the risk of seizures in children with Dravet syndrome, according to the phase III GWPCARE2* study presented at the American Academy of Neurology annual meeting (AAN 2019).